Clay B. Siegall is a common figure in the world of oncology. Clay is the founder and the chief executive officer of a leading biotechnology company that is known as Seattle Genetics. The scientist founded this successful company in the year 1998, and he has been in charge of the major company operations since then. As the chairman of the board of directors and CEO, Clay Siegall has been working so hard to ensure that the company does not lack enough funds. With his excellent skills in leadership, Clay Siegall has taken the company to greater heights in the biotechnology department. Siegall is a trained scientist who has a lot of expertise in cancer treatment, and this is why most of the medications from his company have been performing so well among the cancer patients.
Seattle Genetics came to the limelight several years ago when it introduced its first drug into the global platform. This drug is known as ADCETRIS, and it has been effective in treating various forms of cancer. Clay Siegall and his company have been very proud of the drug since it hit the market several years ago. Clay has a lot of knowledge in genetics, and he used these skills to come up with the drug. At first, medical experts wanted to try the drug and ensure that it was a great way of treating cancer before they can approve it to be used in other parts of the world. Fortunately, most of the people who used the medication came out healthy, and this proved that Clay and his company were in the right direction.
Although ADCETRIS has only been introduced in the company recently, it has already been accepted by the people in more than sixty six nations of the world. All of the countries using the drug praise it because of its few side effects to the cancer patients it is treating. Siegall says that he decided to specialize in cancer treatment when he discovered that most of the cancer treatment options were harsh on the patients who were already weak. The businessman has led a great career life because of his passion for cancer treatment .